J. Walsh
Beaumont Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J. Walsh.
Infection Control and Hospital Epidemiology | 2010
E. Creamer; Anthony Dolan; Orla Sherlock; J. Walsh; J. Moore; E.G. Smyth; E. O'Neill; Anna C. Shore; Derek J. Sullivan; Angela S. Rossney; Robert Cunney; David C. Coleman; Hilary Humphreys
OBJECTIVES (1) To determine whether rapid screening with polymerase chain reaction (PCR) assays leads to the earlier isolation of patients at risk for methicillin-resistant Staphylococcus aureus (MRSA) colonization, (2) to assess compliance with routine MRSA screening protocols, (3) to confirm the diagnostic accuracy of the Xpert MRSA real-time PCR assay (Cepheid) by comparison with culture, and (4) to compare turnaround times for PCR assay results with those for culture results. DESIGN Before-and-after study conducted in a 700-bed acute tertiary care referral hospital. Study periods were (1) a 5-week period before PCR testing began, (2) a 10-week period when the PCR assay was used, and (3) a 5-week period after PCR testing was discontinued. RESULTS Among 489 at-risk patients, MRSA was isolated from 20 (33%) of 60 patients during period 1, 77 (22%) of 349 patients during period 2, and 18 (23%) of 80 patients during period 3. Twenty-two (27%) of 82 at-risk patients were not screened during period 1, compared with 40 (10%) of 389 at-risk patients not screened during period 2 (P < .001). More MRSA-positive patients were preemptively isolated during periods 1 and 3 compared with period 2 (34 [24%] of 140 vs 28 [8%] of 389; P < .001); however, more MRSA-positive patients were isolated after notification of MRSA-positive results during period 2 (47 [13%] of 349) compared with periods 1 and 3 (2 [1%] of 140; P < .001). The sensitivity, specificity, positive predictive value, and negative predictive value of the PCR assay were 95%, 97%, 82%, and 99%, respectively. The mean turnaround time from receipt of specimens in the laboratory to PCR assay result was 2.6 hours. CONCLUSIONS Rapid screening with the Xpert MRSA PCR assay facilitated compliance with screening policies and the earlier isolation of MRSA-positive patients. Discrepant results confirm that PCR testing should be used as a screening tool rather than as a diagnostic tool.
American Journal of Infection Control | 2012
E. Creamer; Sandra Galvin; Anthony Dolan; Orla Sherlock; Borislav D. Dimitrov; Deirdre Fitzgerald-Hughes; J. Walsh; J. Moore; E.G. Smyth; Anna C. Shore; Derek J. Sullivan; Peter M. Kinnevey; Piaras O’Lorcain; Robert Cunney; David C. Coleman; Hilary Humphreys
BACKGROUND Screening for methicillin-resistant Staphylocccus aureus (MRSA) is advocated as part of control measures, but screening all patients on admission to hospital may not be cost-effective. OBJECTIVE Our objective was to evaluate the additional yield of screening all patients on admission compared with only patients with risk factors and to assess cost aspects. METHODS A prospective, nonrandomized observational study of screening nonrisk patients ≤72 hours of admission compared with only screening patients with risk factors over 3 years in a tertiary referral hospital was conducted. We also assessed the costs of screening both groups. RESULTS A total of 48 of 892 (5%) patients was MRSA positive; 28 of 314 (9%) during year 1, 12 of 257 (5%) during year 2, and 8 of 321 (2%) during year 3. There were significantly fewer MRSA-positive patients among nonrisk compared with MRSA-risk patients: 4 of 340 (1%) versus 44 of 552 (8%), P ≤ .0001, respectively. However, screening nonrisk patients increased the number of screening samples by 62% with a proportionate increase in the costs of screening. A backward stepwise logistic regression model identified age > 70 years, diagnosis of chronic pulmonary disease, previous MRSA infection, and admission to hospital during the previous 18 months as the most important independent predictors to discriminate between MRSA-positive and MRSA-negative patients on admission (94.3% accuracy, P < .001). CONCLUSION Screening patients without risk factors increased the number of screenings and costs but resulted in few additional cases being detected. In a hospital where MRSA is endemic, targeted screening of at-risk patients on admission remains the most efficient strategy for the early identification of MRSA-positive patients.
Journal of Hospital Infection | 2010
M. Morris-Downes; E.G. Smyth; J. Moore; Fidelma Fitzpatrick; J. Walsh; V. Caffrey; A. Morris; S. Foley; Hilary Humphreys
Vancomycin-resistant enterococci (VRE) are prevalent in many Irish hospitals. We analysed surveillance data from 2001 to 2008 in a centre where VRE is endemic. All clinically significant enterococci were tested for susceptibility to vancomycin. All intensive care unit admissions were screened on admission and weekly thereafter. Interventions included isolating/cohorting VRE patients, monthly prevalence surveys of VRE patients, the introduction of an electronic alert system, programmes to improve hand and environmental hygiene, and the appointment of an antibiotic pharmacist. There was a significant increase in the number of positive VRE screening samples from 2001 (1.96 patients with positive VRE screens per 10 000 bed-days) to 2006 (4.98 per 10 000 bed-days) (P < or = 0.001) with a decrease in 2007 (3.18 per 10 000 bed-days) (P < or = 0.01). The number of VRE bloodstream infections (BSI) increased from 0.09 BSI per 10 000 bed-days in 2001 to 0.78 per 10 000 bed-days in 2005 (P < or = 0.001) but decreased subsequently. Linear regression analysis indicated a significant association between new cases of VRE and non-isolated VRE patients, especially between May 2005 and December 2006 [P=0.009; 95% confidence interval (CI): 0.08-0.46] and between May 2005 and December 2008 (P = 0.008; 95% CI: 0.06-0.46). Routine surveillance for VRE together with other measures can control VRE BSI and colonisation, even where VRE is endemic, and where facilities are constrained.
Journal of Hospital Infection | 2010
E. Creamer; Sarah Dorrian; Anthony Dolan; Orla Sherlock; Deirdre Fitzgerald-Hughes; J. Walsh; Anna C. Shore; Derek J. Sullivan; Peter M. Kinnevey; Angela S. Rossney; Robert Cunney; David C. Coleman; Hilary Humphreys
Journal of Hospital Infection | 2007
T. Doherty; J. Walsh; J. Moore; M. Morris-Downes; E.G. Smyth; Hilary Humphreys
Journal of Hospital Infection | 2017
Toney Thomas Poovelikunnel; Fionnuala Duffy; C. Finn; Fiona McCormack; J. Walsh; Hilary Humphreys
/data/revues/01956701/v75i2/S0195670109005477/ | 2011
E. Creamer; S Dorrian; Anthony Dolan; Orla Sherlock; Deirdre Fitzgerald-Hughes; J. Walsh; Anna C. Shore; Derek J. Sullivan; Peter M. Kinnevey; Angela S. Rossney; Robert Cunney; David C. Coleman; Hilary Humphreys
Journal of Hospital Infection | 2010
E. Creamer; Anthony Dolan; Orla Sherlock; Deirdre Fitzgerald-Hughes; J. Walsh; Anna C. Shore; Derek J. Sullivan; Peter M. Kinnevey; Angela S. Rossney; P. O'Lorcain; E.G. Smyth; Robert Cunney; David C. Coleman; Hilary Humphreys
Journal of Hospital Infection | 2010
J. Walsh; C. Finn; F. Duffy; F. McCormack; M. Downes; E. Smith; Fidelma Fitzpatrick; Hilary Humphreys
Journal of Hospital Infection | 2010
J. Walsh; C. Finn; F. Duffy; F. McCormack